Tenaya Therapeutics Faces Multiple Analyst Price Target Cuts Following Capital Raise
Morgan Stanley, Canaccord Genuity, and H.C. Wainwright have lowered price targets for Tenaya Therapeutics after a $60 million public offering, while maintaining positive ratings.